FindTrial
Sign In

Efficacy of Submucosal Tramadol and Lidocaine on Success Rate of Inferior Alveolar Nerve Block in Mandibular Molars with Symptomatic Irreversible Pulpitis

Efficacy of Submucosal Tramadol and Lidocaine on Success Rate of Inferior Alveolar Nerve Block in Mandibular Molars with Symptomatic Irreversible Pulpitis: A Randomized, Controlled, Double-Blind Clinical Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20190509004
Enrollment
Unknown
Registered
2019-05-09
Start date
2018-11-10
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with symptomatic irreversible pulpitis Irreversible pulpitis

Interventions

5 minutes after the first inferior alveolar nerve block (IANB)&#44
submucosal 100 mg/2 ml tramadol was administrated to the mucobuccal fold of mandibular molar in tramadol group.,5 minutes after the first inferior alveolar nerve block (IANB)&#44
submucosal 40 mg/2 ml lidocaine was administrated to the mucobuccal fold of mandibular molar in lidocaine group.,5 minutes after the first inferior alveolar nerve block (IANB)&#44
2 ml saline were administrated to the mucobuccal fold of mandibular molar in control group.
Experimental Other,Experimental Other,Placebo Comparator Other
Submucosal Tramadol,Submucosal Lidocaine,Control

Sponsors

none
Lead Sponsor
none,none
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. A single mandibular molar tooth responding to cold test for a long time and diagnosed with symptomatic irreversible pulpitis 2. Patients with preoperative pain scores ranging from moderate to severe (55–170 mm) on a Heft-Parker visual analog scale (HP VAS, 0–170 mm) 3. The absence of periapical radiolucency on periapical radiography (except enlarged periodontal ligaments not larger than 0.75-1 mm) 4. Have the ability to understand the informed consent form and pain record scales to be used within the study

Exclusion criteria

Exclusion criteria: 1. Receiving analgesic or anti-inflammatory drugs within 24 hours prior to treatment 2. Allergy or susceptibility to any opioid or nonopioid analgesia, including lidocaine, tramadol or NSAIDs 3. Pregnant or nursing, those with any bleeding problem or those using anticoagulant medication 4. Patients have not lip numbness following initial IANB injection 4. In addition to hypersensitive teeth to percussion and palpation; teeth have calcified root canals, periodontal diseases, root resorption, open apex, necrotic pulp and have already been undergone root canal treatment were excluded from the study.

Design outcomes

Primary

MeasureTime frame
pulpal anesthesia 15 minutes HP VAS Scale—

Secondary

MeasureTime frame
preparation pain 15 minutes HP VAS Scale—

Countries

Turkey

Contacts

Public ContactFatih Aksoy

Adıyaman University, Faculty of Dentistry

dr.f.aksoy@gmail.com+90 542 342 88 07

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026